Pharming Group N.V.
DB:PHG Stock Report
Pharming Group Balance Sheet Health
Financial Health criteria checks 5/6 Pharming Group has a total shareholder equity of $225.8M and total debt of $95.4M, which brings its debt-to-equity ratio to 42.3%. Its total assets and total liabilities are $425.5M and $199.7M respectively.
Key information
42.3%
Debt to equity ratio
Interest coverage ratio n/a Cash US$171.77m Equity US$225.79m Total liabilities US$199.72m Total assets US$425.51m
Recent financial health updates
Show all updates
Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation Oct 10
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union Jun 02
Pharming Group N.V. Provides Revenue Guidance for 2024 May 09 Pharming Group N.V. announced that it expects to receive €100 million in funding Apr 20
Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024
Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024 Dec 19
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director Sep 26
Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan Aug 09
Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer Aug 03
Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor May 18
Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe Feb 18
Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition Dec 15 Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023
Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib Dec 08
Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib Oct 29
Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib Oct 11
Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib Sep 28
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency Aug 02
Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS Aug 01 GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM). May 13
Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA Apr 26 GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million. Apr 23
Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting Apr 03
Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome Feb 02
Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe Jan 06
Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST® Sep 15
Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome Jun 24 Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021 Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021
Financial Position Analysis
Short Term Liabilities: PHG's short term assets ($282.2M) exceed its short term liabilities ($79.8M).
Long Term Liabilities: PHG's short term assets ($282.2M) exceed its long term liabilities ($119.9M).
Debt to Equity History and Analysis
Debt Level: PHG has more cash than its total debt.
Reducing Debt: PHG's debt to equity ratio has reduced from 59.8% to 42.3% over the past 5 years.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHG has sufficient cash runway for more than 3 years based on its current free cash flow .
Forecast Cash Runway: Insufficient data to determine if PHG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}